- Oops!Something went wrong.Please try again later.
Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results.
Earnings per share rose 7.77% year over year to $1.11, which beat the estimate of $1.10.
Revenue of $1,140,000,000 decreased by 6.02% year over year, which were in line with the estimate of $1,140,000,000.
The upcoming fiscal year's EPS expected to be between $4.09 and $4.38.
The upcoming fiscal year's revenue expected to be between $5,125,000,000 and $5,325,000,000.
How To Listen To The Conference Call
Date: Feb 18, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/h8kqo86z
Recent Stock Performance
Company's 52-week high was at $81.35
Company's 52-week low was at $30.02
Price action over last quarter: Up 47.21%
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.